Revolution Medicines rises as FDA clears expanded access pathway for daraxonrasib

Revolution Medicines (RVMD) is up 5.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The stock appears to be moving higher on fresh investor focus around U.S. regulators allowing an expanded access treatment protocol for the company’s investigational pancreatic cancer drug daraxonrasib (RMC-6236). Expanded access does not equal approval, but it can be interpreted as a sign of regulatory momentum and near-term visibility ahead of additional clinical disclosures.

Details:

The FDA said it issued a “safe to proceed” letter allowing an expanded access treatment protocol for daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma.

The FDA stated it received the expanded access request on April 28, 2026 and signed it on April 30, 2026, with the announcement dated May 1, 2026.

Revolution Medicines said the program is intended to provide access in a controlled and monitored setting and that requests must be initiated by a licensed treating physician (not directly by patients or caregivers).

Separately, the company has highlighted that detailed Phase 3 RASolute 302 results for daraxonrasib are scheduled for presentation at the 2026 ASCO Annual Meeting, which can keep attention elevated around the asset.

Sources:

U.S. Food and Drug Administration, Revolution Medicines Investor Relations, The ASCO Post

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RVMD Insider Trading Activity

$RVMD insiders have traded $RVMD stock on the open market 49 times in the past 6 months. Of those trades, 0 have been purchases and 49 have been sales.

Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:

MARK A GOLDSMITH (See Remarks) has made 0 purchases and 22 sales selling 320,265 shares for an estimated $33,591,043.
MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 5 sales selling 84,430 shares for an estimated $8,370,274.
ANTHONY MANCINI (See Remarks) has made 0 purchases and 8 sales selling 40,570 shares for an estimated $3,991,949.
JACK ANDERS (Chief Financial Officer) has made 0 purchases and 5 sales selling 31,275 shares for an estimated $2,534,090.
JEFF CISLINI (General Counsel) has made 0 purchases and 5 sales selling 19,942 shares for an estimated $1,542,346.
STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 2 sales selling 9,749 shares for an estimated $846,387.
LIN WEI (Chief Medical Officer) sold 2,073 shares for an estimated $206,222
XIAOLIN WANG (See Remarks) sold 2,010 shares for an estimated $199,955

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$RVMD Hedge Fund Activity

We have seen 246 institutional investors add shares of $RVMD stock to their portfolio, and 151 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,482,061 shares (-72.8%) from their portfolio in Q4 2025, for an estimated $277,346,158
WELLINGTON MANAGEMENT GROUP LLP removed 2,825,797 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $225,074,731
AVORO CAPITAL ADVISORS LLC added 2,170,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $172,840,500
JPMORGAN CHASE & CO removed 2,076,700 shares (-83.1%) from their portfolio in Q4 2025, for an estimated $165,409,155
UBS GROUP AG added 1,998,972 shares (+183.6%) to their portfolio in Q4 2025, for an estimated $159,218,119
A16Z CAPITAL MANAGEMENT, L.L.C. removed 1,827,424 shares (-66.5%) from their portfolio in Q4 2025, for an estimated $145,554,321
LUNATE CAPITAL LTD removed 1,647,150 shares (-75.0%) from their portfolio in Q1 2026, for an estimated $160,185,337

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$RVMD Analyst Ratings

Wall Street analysts have issued reports on $RVMD in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 01/20/2026
Wolfe Research issued a "Outperform" rating on 11/18/2025
Wedbush issued a "Outperform" rating on 11/06/2025
Needham issued a "Buy" rating on 11/06/2025
HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
JP Morgan issued a "Overweight" rating on 11/06/2025

To track analyst ratings and price targets for $RVMD, check out Quiver Quantitative's $RVMD forecast page.

$RVMD Price Targets

Multiple analysts have issued price targets for $RVMD recently. We have seen 15 analysts offer price targets for $RVMD in the last 6 months, with a median target of $165.0.

Here are some recent targets:

Robert Burns from HC Wainwright & Co. set a target price of $169.0 on 04/22/2026
Jonathan Chang from Leerink Partners set a target price of $171.0 on 04/22/2026
Ami Fadia from Needham set a target price of $186.0 on 04/20/2026
Laura Prendergast from Stifel set a target price of $215.0 on 04/20/2026
Robert Driscoll from Wedbush set a target price of $147.0 on 04/14/2026
Michael Schmidt from Guggenheim set a target price of $175.0 on 04/14/2026
Cory Kasimov from Evercore ISI Group set a target price of $200.0 on 04/14/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.